SEARCH UCD

Advanced Search
 
 
Twitter Linked In facebook button
 
 

3D NET

Work Packages The 3D-NET project will run for 4 years (Sept 2013 – Sept 2017) and has been structured in 3 different Research Work Packages (WPs) which are summarized below. Current Vacancies available in 3D-NET are shown at the end of this page.

 

Work Package 1: Discovery of Drugs with Novel Anti-Angiogenic Efficacy in the Eye

Neovascularisation is a pathological hallmark in prevalent forms of blindness. Opportunities exist to develop more effective, safer, cheaper and more easily administered anti-angiogenic drugs for the eye than those currently prescribed (e.g. bevacizumab).

1.Novel small molecule drugs that inhibit angiogenesis in the zebrafish eye will be discovered, validated in human cell lines, structurally modified to enhance efficacy/delivery and ranked.

2.Selected, highest ranking novel drugs will be tested in pre-clinical mouse models of ocular neovascularisation to determine if they surpass the current gold standard.

 ‌

CHEMICAL SCREEN IN ZEBRAFISH: DISCOVERY OF DRUGS ABLE TO INFLUENCE THE DEVELOPMENT OF THE OCULAR VESSELS

C‌HEMICAL SCREEN IN ZEBRAFISH: DISCOVERY OF DRUGS ABLE TO INFLUENCE THE DEVELOPMENT OF THE OCULAR VESSELS

 

Work Package 2: Discovery & Development of Small Molecule Drugs that Reduce Ocular Inflammation or Retinal Vasculature Permeability

Anterior or posterior eye inflammation and hyper-permeability of the retinal vasculature leading to retinal/macular oedema are pathological features of common forms of blindness. Opportunities exist to develop more effective, safer, cheaper and more easily administered drugs that reduce ocular inflammation or RVP than those currently prescribed (e.g. Lucentis).

1. Novel small molecule drugs that inhibit ocular inflammation and/or retinal vascular permeability in cells andzebrafish models will be discovered and structurally modified to enhance efficacy.

2. The efficacy of selected, novel drugs compared to current gold standards is determined in pre-clinical mouse and porcine models of ocular inflammation and RVP.

 

Synthetic Chemistry Facilities in Gadea

 

 

Work Package 3: Development of Small Molecule Compounds with “Cell Protective” Activity in the Eye

Blindness is commonly associated with damage to the cornea or degeneration of retinal cells. Here, we seek to discover novel drugs that protect the eye against these insults.

1. Novel small molecule oculoprotective drugs will be discovered and validated in human cell lines and zebrafishmodels and structurally modified to enhance efficacy.

2. Selected, highest ranking, novel oculoprotective drugs will be tested in porcine explant and mouse pre-clinical mouse models of ocular damage, to determine if they surpass the current gold standard.

Current Vacancies

  • No Current Position Available

Previous positions advertised:
  • Post-doctoral Research Fellow, level 3 in Trinity Centre for Health Sciences, Dublin
    (closed on 29/05/2015)
  • Post-doctoral Research Scientist (Pharmacologist) in KalVista, UK
    (closed on 05/02/2015)
  •  Post Doc Research Position in RenaSci, UK
    (closed on 15/12/2014)
  • Post Doc /Research fellow position in IOBA-University of Valladolid
    (closed on 23/06/2014)
  • SFI Funded: Post Doc/ Research Assistant in UCD
    (closed on 14/02/2014)
  • Post Doc Research Position in Gadea Grupo Farmacéutico
    (closed on 20/12/2013)
  • Post Doc Research Fellow Position in UCD
    (closed on 28/11/2013)
  • Master of Science Research Position in UCD, Dublin.
    (closed on 21/08/2015)
  • Post Doc Research Position in RenaSci, UK.
    (closed on 15/12/2015)